Clinical Trials
45 trialsA Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
Eli Lilly and Company
FourLight-3
Pfizer
SERENA-1
AstraZeneca
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer
National Cancer Institute (NCI)
monarchE
Eli Lilly and Company
CYCLONE 2
Eli Lilly and Company
SERENA-6
AstraZeneca
PIKASSO-01
Eli Lilly and Company
FAIM
Royal Marsden NHS Foundation Trust
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Alliance for Clinical Trials in Oncology
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Eli Lilly and Company
Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis
National Institutes of Health Clinical Center (CC)
CARABELA
Spanish Breast Cancer Research Group
BOUQUET
Hoffmann-La Roche
Abemaciclib and Letrozole to Treat Endometrial Cancer
GOG Foundation
Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
M.D. Anderson Cancer Center
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Dana-Farber Cancer Institute
Abemaciclib With or Without Atezolizumab for mCRPC
Dana-Farber Cancer Institute
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
Pfizer
JUNIPER
Eli Lilly and Company
Next MONARCH 1
Eli Lilly and Company
MONARCH plus
Eli Lilly and Company
MONARCH 3
Eli Lilly and Company
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Eli Lilly and Company
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
Eli Lilly and Company
postMONARCH
Eli Lilly and Company
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
Dana-Farber Cancer Institute
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
University of Washington
POETIC-A
Institute of Cancer Research, United Kingdom
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
Pfizer
CLONEVO
Weill Medical College of Cornell University
MONARCH 2
Eli Lilly and Company
AMBRE
UNICANCER
A Study of Abemaciclib in Recurrent Glioblastoma
Dana-Farber Cancer Institute
EMBER-3
Eli Lilly and Company
Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors
Memorial Sloan Kettering Cancer Center
ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer
Ono Pharmaceutical Co., Ltd.
CYCLONE 3
Eli Lilly and Company
BRAVE-Cyclin
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study of Abemaciclib in Dedifferentiated Liposarcoma
Memorial Sloan Kettering Cancer Center
EMBER
Eli Lilly and Company
Abemaciclib in Patients with Oligodendroglioma
Abramson Cancer Center at Penn Medicine
Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance
University of California, San Diego